The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments

被引:6
作者
Webb, Edward J. D. [1 ]
Meads, David M. [1 ]
Eskyte, Ieva [2 ]
Ford, Helen L. [3 ]
Bekker, Hilary L. [1 ]
Chataway, Jeremy [4 ,5 ]
Pepper, George [6 ]
Marti, Joachim [7 ]
Okan, Yasmina [8 ]
Pavitt, Sue H. [9 ]
Schmierer, Klaus [10 ,11 ]
Manzano, Ana [12 ]
机构
[1] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England
[2] Univ Leeds, Sch Law, Leeds, W Yorkshire, England
[3] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[4] UCL, Queen Sq Multiple Sclerosis Ctr, Dept Neuroinflammat, UCL Queen Sq Inst Neurol,Fac Brain Sci, London WC1B 5EH, England
[5] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England
[6] ShiftMs, London, England
[7] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante, Lausanne, Switzerland
[8] Univ Leeds, Leeds Univ, Ctr Decis Res, Business Sch, Leeds, W Yorkshire, England
[9] Univ Leeds, Sch Dent, Dent Translat & Clin Res Unit, Leeds, W Yorkshire, England
[10] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst Neurosci Surg & Trauma, London, England
[11] Barts Hlth NHS Trust, Royal London Hosp, Clin Board Med Neurosci, London, England
[12] Univ Leeds, Sch Sociol & Social Policy, Leeds, W Yorkshire, England
关键词
DISCRETE-CHOICE EXPERIMENTS; CONJOINT-ANALYSIS; PROFESSIONALS PREFERENCES; PATIENT PREFERENCES; PREGNANCY; THERAPIES; DIAGNOSIS; ATTRIBUTES; PEOPLE; TESTS;
D O I
10.1007/s40271-020-00429-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Relapsing-remitting multiple sclerosis (RRMS) is an incurable disease characterised by relapses (periods of function loss) followed by full or partial recovery, and potential permanent disability over time. Many disease-modifying treatments (DMTs) exist that help reduce relapses and slow disease progression. Most are contraindicated during conception/pregnancy and some require a discontinuation period before trying to conceive. Although around three-quarters of people with RRMS are women, there is limited knowledge about how reproductive issues impact DMT preference. Objective The aim of this study was to measure the preferences for DMTs of women with RRMS who are considering pregnancy. Design An online discrete choice experiment (DCE). Methods Participants chose between two hypothetical DMTs characterised by a set of attributes, then indicated if they preferred their choice to no treatment. Attributes were identified from interviews and focus groups with people with RRMS and MS professionals, as well as literature reviews, and included the probability of problems with pregnancy, discontinuation of DMTs, and breastfeeding safety. In each DCE task, participants were asked to imagine making decisions in three scenarios: now; when trying to conceive; and when pregnant. Analysis Two mixed logit models were estimated, one to assess the statistical significance between scenarios and one in maximum acceptable risk space to allow comparison of the magnitudes of parameters between scenarios. Sample Women with RRMS who were considering having a child in the future, recruited from a UK MS patient register. Results Sixty respondents completed the survey. Participants preferred no treatment in 12.6% of choices in the 'now' scenario, rising significantly to 37.6% in the 'trying to conceive' scenario and 60.3% in the 'pregnant' scenario (Kruskal-Wallisp < 0.001). This pattern corresponds with results from models that included a no-treatment alternative-specific constant (ASC) capturing differences between taking and not taking a DMT not specified by the attributes. The ASC was lower in the trying to conceive scenario than in the now scenario, and lower still in the pregnant scenario, indicating an intrinsic preference for no treatment. Participants also placed relatively less preference on reducing relapses and avoiding disease progression in the trying to conceive and pregnant scenarios compared with a lower risk of problems with pregnancy. In the trying to conceive scenario, participants' preference for treatments with shorter washout periods increased. Conclusion Women with RRMS considering having a child prefer DMTs with more favourable reproduction-related attributes, even when not trying to conceive. Reproductive issues also influenced preferences for DMT attributes not directly related to pregnancy, with preferences dependent on the life circumstances in which choices were made. The design of the DCE highlights the benefits of considering the scenario in which participants make choices, as they may change over time.
引用
收藏
页码:583 / 597
页数:15
相关论文
共 50 条
  • [21] Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment
    Manuel Garcia-Dominguez, Jose
    Munoz, Delicias
    Comellas, Marta
    Gonzalbo, Irmina
    Lizan, Luis
    Polanco Sanchez, Carlos
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 1945 - 1956
  • [22] Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity
    Bsteh, Gabriel
    Aicher, Marie L.
    Walde, Janette F.
    Krajnc, Nik
    Haider, Lukas
    Traxler, Gerhard
    Gradl, Christiane
    Salmen, Anke
    Riedl, Katharina
    Poskaite, Paulina
    Leyendecker, Philipp
    Altmann, Patrick
    Auer, Michael
    Berek, Klaus
    Di Pauli, Franziska
    Kornek, Barbara
    Leutmezer, Fritz
    Rommer, Paulus S.
    Zulehner, Gudrun
    Zrzavy, Tobias
    Deisenhammer, Florian
    Chan, Andrew
    Berger, Thomas
    Hoepner, Robert
    Hammer, Helly
    Hegen, Harald
    NEUROLOGY, 2024, 103 (06)
  • [23] Injectable Disease-Modifying Therapy for Relapsing-Remitting Multiple Sclerosis: A Review of Adherence Data
    Caon, Christina
    Saunders, Carol
    Smrtka, Jennifer
    Baxter, Nancy
    Shoemaker, Jennifer
    JOURNAL OF NEUROSCIENCE NURSING, 2010, 42 (05) : S5 - S9
  • [24] Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study
    Villaverde-Gonzalez, Ramon
    Candeliere-Merlicco, Antonio
    Aranzazu Alonso-Frias, Maria
    Aparicio Castro, Eladio
    Carrillo Alcaraz, Andres
    Mallada Frechin, Javier
    Perez Sempere, Angel
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [25] Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
    Oreja-Guevara, Celia
    Martinez-Yelamos, Sergio
    Eichau, Sara
    Llaneza, Miguel Angel
    Martin-Martinez, Jesus
    Pena-Martinez, Joaquin
    Meca-Lallana, Virginia
    Alonso-Torres, Ana Maria
    Moral-Torres, Ester
    Rio, Jordi
    Calles, Carmen
    Ares-Luque, Adrian
    Ramio-Torrenta, Lluis
    Marzo-Sola, Maria Eugenia
    Prieto, Jose Maria
    Martinez-Gines, Maria Luisa
    Arroyo, Rafael
    Otano-Martinez, Maria Angeles
    Brieva-Ruiz, Luis
    Gomez-Gutierrez, Montserrat
    Rodriguez-Antiguedad, Alfredo
    Sanchez-Seco, Victoria Galan
    Costa-Frossard, Lucienne
    Hernandez-Perez, Miguel Angel
    Landete-Pascual, Lamberto
    Gonzalez-Platas, Montserrat
    Meca-Lallana, Jose E.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [26] Disease-modifying therapies in Chinese children with multiple sclerosis
    Yang, Fen
    Huang, De-hui
    Yang, Yang
    Wu, Wei-ping
    TURKISH JOURNAL OF PEDIATRICS, 2014, 56 (05) : 482 - 486
  • [27] Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
    Ng, Huah Shin
    Zhu, Feng
    Kingwell, Elaine
    Yao, Shenzhen
    Ekuma, Okechukwu
    Evans, Charity
    Fisk, John D.
    Marrie, Ruth Ann
    Zhao, Yinshan
    Tremlett, Helen
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (05):
  • [28] Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
    Portaccio, Emilio
    Fonderico, Mattia
    Iaffaldano, Pietro
    Pasto, Luisa
    Razzolini, Lorenzo
    Bellinvia, Angelo
    De Luca, Giovanna
    Ragonese, Paolo
    Patti, Francesco
    Morra, Vincenzo Brescia
    Cocco, Eleonora
    Sola, Patrizia
    Inglese, Matilde
    Lus, Giacomo
    Pozzilli, Carlo
    Maimone, Davide
    Lugaresi, Alessandra
    Gazzola, Paola
    Comi, Giancarlo
    Pesci, Ilaria
    Spitaleri, Daniele
    Rezzonico, Marta
    Vianello, Marika
    Avolio, Carlo
    Logullo, Francesco O.
    Granella, Franco
    Salvetti, Marco
    Zaffaroni, Mauro
    Lucisano, Giuseppe
    Filippi, Massimo
    Trojano, Maria
    Amato, Maria Pia
    JAMA NEUROLOGY, 2022, 79 (09) : 869 - 878
  • [29] Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review
    Capone, Fioravante
    Albanese, Angela
    Quadri, Giorgia
    Di Lazzaro, Vincenzo
    Falato, Emma
    Cortese, Antonio
    De Giglio, Laura
    Ferraro, Elisabetta
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [30] The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis
    Wickstrom, Anne
    Fagerstrom, Maria
    Wickstrom, Lucas
    Granasen, Gabriel
    Dahle, Charlotte
    Vrethem, Magnus
    Sundstrom, Peter
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (08) : 1137 - 1147